Geodon Labeling Changes Still Under Discussion, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report